Anticancer Drug Discovery and Development: Natural Products and New Molecular Models

1. Front Matter

   Pages i-xi

   PDF

2. Discovery of Natural Products from Microalgae and Marine Organisms

   • Fred Valeriote, Richard E. Moore, Gregory M. L. Patterson, Valerie J. Paul, Paul J. Scheuer, Thomas Corbett

   Pages 1-25

3. Discovery of Naturally Occurring Antitumor Agents

   • Ching-Jer Chang, Curtis L. Ashendel, Robert L. Geahlen, Jerry L. McLaughlin

   Pages 27-37

4. Marine Invertebrates and Microbes as Sources of Potential Antitumor Compounds

   • Andrew L. Staley, Jon Clardy

   Pages 39-61

5. Novel Strategies for the Discovery of Plant-Derived Anticancer Agents

   • Geoffrey A. Cordell, Norman R. Farnsworth, Christopher W. W. Beecher, D. Doel Soejarto, A. Douglas Kinghorn, John M. Pezzuto et al.

   Pages 63-83

6. A Strategy for Identifying Novel Inhibitors of DNA Topoisomerase I

   • Sidney M. Hecht, David E. Berry, Laurie J. Mackenzie, Elva A. Shultis, James A. Chan

   Pages 85-94

7. Altromycins: A New Family of Antitumor Antibiotics-Discovery and Biological Evaluation

   • J. B. McAlpine, J. P. Karwowski, M. Jackson, G. M. Brill, S. Kadam, L. Shen et al.

   Pages 95-117

8. Suppression of Human Melanoma Metastasis in SCID Mice with Antibodies to the EGF-Receptor

   • B. M. Mueller, R. A. Reisfeld

   Pages 119-125

9. Growth Factor and Oncogene Signalling as a Target for Anticancer Drug Development

   • Garth Powis

   Pages 127-148

10. Nucleoside and Nucleotide Modulation of Oncogenic Expression: A New Approach to Cancer Chemotherapy

    • Roland K. Robins, Rick A. Finch, Thomas L. Avery

    Pages 149-182

11. Interferons in Cancer Therapy: From Clinical Trials to New Potentials in Anticancer Drug Discovery and Development

    • Gerhard G. Steinmann, Gunther R. Adolf, Gerhard Leitz

    Pages 183-208

12. Selection and Manipulation of Immunoglobulins for Radionuclide Delivery

    • Z. Steplewski, P. Curtis, J. Hainfeld, R. Mease, S. Srivastava

    Pages 209-233

13. Microorganisms: Strategic Sources of Novel Antitumor Agents

    • Josefino B. Tunac

    Pages 235-267

14. The Therapeutic Potential of Novel Pure Antiestrogens

    • A. E. Wakeling

    Pages 269-282

15. Preclinical Pharmacology and Phase I Clinical Trials of TaxotereR (RP 56976, NSC 628503)

    • Marie-Christine Bissery, Howard Burris, Richard Pazdur

    Pages 283-297

16. Bropirimine, a Small-Molecule Biological Response Modifier and an Effective Antitumor Agent

    • Li H. Li

    Pages 299-345

17. Determinants of Etoposide Cytotoxicity in Vitro

    • Richard B. Lock

    Pages 347-363

18. Screening for Anticancer Leads from Marine Organisms in a Mechanism-Based Drug Discovery Program

    • P. Crews, D. L. Slate, W. H. Gerwick, F. J. Schmitz, R. Schatzman, B. Strulovici et al.

    Pages 365-403

With the publication of these proceedings from the Second Drug Discovery and Development Symposium, this forum has become the main mechanism for bringing together the principal groups involved in both discovering and developing new approaches to the treatment of cancer. This Second Symposium emphasized the types of materials being discovered and their therapeutic activity. This is especially evident in the natural product discovery programs, where unique and active structures are being identified.
The major contributors to the meeting were the investigators participating in the National Cooperative (Natural Products) Drug Discovery Groups [NC(NP)DDG]. These groups reflect an association among researchers at universities or cancer centers, pharmaceutical companies and the National Cancer Institute. Their sources of materials are varied, reflecting chemical inventories of pharmaceutical companies, organic synthetic compounds from the laboratory, cytotoxics as well as biologics and their hybrids, and natural products obtained from plants, marine organisms and microorganisms. The models employed in the discovery systems vary from broadly cellular based to specific enzymes to defined cellular functions. Each of them is believed important to the malignant state and will allow for the discovery of compounds which will have efficacy in cancer therapy.
The goal of the participants is both to discover new anticancer agents and to develop them as efficiently as possible into clinically useful additions to treatment. Of importance is the fact that there are a number of promising leads which will soon be moving into the clinic thereby testing the effectiveness of this NC (NP) DDG approach.

• DNA
• antibiotics
• cancer
• cancer therapy
• chemotherapy
• clinical trial
• drug
• drug discovery
• interferon
• melanoma
• metastasis
• oncogene
• pharmacology
• research
• screening

• School of Medicine, Wayne State University, Detroit, USA

  Frederick A. Valeriote, Thomas H. Corbett, Laurence H. Baker

Policies and ethics